iSpecimen Inc. Enacts 1-for-40 Reverse Stock Split to Maintain Nasdaq Listing; Validates Prior Defective Split

summarizeSummary

iSpecimen Inc. formally implemented a 1-for-40 reverse stock split to meet Nasdaq listing requirements and also validated a previously defective 1-for-20 reverse split from 2024.

check_boxKey Events

• 1-for-40 Reverse Stock Split Effectuated

  The company filed a Fifth Amended and Restated Certificate of Incorporation to effectuate a 1-for-40 reverse stock split, which became effective on April 27, 2026. This follows the news release on April 24, 2026, announcing the split.

• Share Count Significantly Reduced

  The reverse split reduced the number of issued and outstanding common shares from 52,639,796 to approximately 1,316,032, without changing the par value per share.

• Aimed at Nasdaq Compliance and Investor Attraction

  The reverse stock split is intended to increase the per-share trading price to regain compliance with Nasdaq's minimum bid price requirement and to better position the company to attract institutional and other investors.

• Prior Defective Reverse Split Validated

  The company also ratified and validated a prior 1-for-20 reverse stock split from September 13, 2024, which was defectively filed due to the omission of a required certificate of amendment.

auto_awesomeAnalysis

This 8-K filing confirms the 1-for-40 reverse stock split, which became effective on April 27, 2026, and was previously announced via press release. The primary purpose of the split is to increase the per-share trading price to regain compliance with Nasdaq's minimum bid price requirement and attract institutional investors. This action is critical for the company's continued listing, especially given its previously reported 79% revenue decline and 'going concern' doubt. Furthermore, the filing reveals and validates a prior 1-for-20 reverse stock split from September 2024 that was defectively filed, raising concerns about past corporate governance practices. Investors should monitor the company's ability to maintain Nasdaq compliance and its operational performance following this significant capital structure change.